Episealer® Knee System IDE Clinical Study

• ClinicalTrials.gov Identifier: NCT04000659
• Recruitment Status: Recruiting
• First Posted: June 27, 2019
• Last Update Posted: December 7, 2022
• Sponsor: Episurf Medical Inc.
• Collaborator: MCRA
• Information provided by (Responsible Party): Episurf Medical Inc.

Study Description

Brief Summary:

The study is a randomized, prospective, multicenter, controlled clinical trial of the Episealer Knee System. The Episealer Knee System is intended for subjects with up to two focal femoral knee chondral or osteochondral lesion that is causing pain and/or disability and requires surgical treatment.

Condition or disease	Intervention/treatment	Phase
Degenerative Lesion of Articular Cartilage of Knee	Device: Episealer Knee System; Procedure: Microfracture	Not Applicable

Detailed Description:

The primary objective of this study is to evaluate the safety and clinical effectiveness of the Episealer Knee System (Episealer Trochlea Solo, Episealer Femoral Twin, and Episealer Condyle Solo) compared to microfracture (with or without debridement) in a group of subjects that require repair of up to 2 focal femoral chondral or osteochondral lesions in the knee.

Clinical success will be analyzed via subject reported outcomes to measure function and pain improvements as compared to baseline, incidence of secondary surgical interventions for the treated knee, absence of subsidence or migration through radiographic assessment, and assessment of weight-bearing status.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 180 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: A total of 180 subjects will be enrolled and randomized using a 2:1 ratio (Episealer: Microfracture). Within each site, subjects will be randomized into one of the two study arms using a blocked randomization scheme with varying block sizes.
• Masking: Single (Participant)
• Masking Description: In this investigation, neither the investigator nor the subject can be blinded to the treatment group assignment due to the implant's distinctive form that can be detected on radiographs; however, the randomization assignment will not be disclosed to the subject until after surgery is performed.
• Primary Purpose: Treatment
• Official Title: A Prospective, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Effectiveness of the Episealer® Knee System Compared to Microfracture for the Treatment of Focal Femoral Knee Chondral or Osteochondral Lesions
• Actual Study Start Date: June 18, 2020
• Estimated Primary Completion Date: June 2024
• Estimated Study Completion Date: June 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Episealer Knee System; The experimental arm will comprise of subjects that will be treated with the Episealer Knee System.	Device: Episealer Knee System; The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
Placebo Comparator: Microfracture; The control arm will comprise of subjects that will receive a Microfracture surgery.	Procedure: Microfracture; Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.

Outcome Measures

Primary Outcome Measures :

1. Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) Subscores [ Time Frame: 24 Months ]
   This endpoint will examine the change in KOOS subscores at 24 months
2. Change in Visual Analog Scale (VAS) Pain Scores [ Time Frame: 24 Months ]
   This endpoint will examine the change in VAS Pain scores at 24 months
3. Incidence of Secondary Surgical Intervention [ Time Frame: 24 Months ]
   This endpoint will examine the incidence of Secondary Surgical Interventions (SSIs) at 24 months
4. Incidence of subsidence or migration at 24 months [ Time Frame: 24 Months ]
   This endpoint will examine the incidence of subsidence/migration at 24 months
5. Weight bearing status [ Time Frame: 8 weeks ]
   This endpoint will examine the weight bearing status at 8 weeks

Secondary Outcome Measures :

1. Change in the KOOS Subscores at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months, and 24-months ]
   This endpoint will examine the change in KOOS subscores at all follow-up time points
2. Change in VAS Pain score at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months, and 24-months ]
   This endpoint will examine the change in VAS Pain scores at all follow-up time points
3. Change in 12-Item Short Form Survey (SF-12) score at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months, and 24-months ]
   This endpoint will examine the change in SF-12 scores at all follow-up time points
4. Incidence of radiographic findings at all follow-up time points [ Time Frame: 8 weeks, 12-months, and 24-months ]
   This endpoint will examine the incidence of radiographic findings at all follow-up time points
5. Incidence of adverse events and device deficiencies at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months and 24-months ]
   This endpoint will examine the safety via the incidence of adverse events and device deficiencies at all follow-up time points

Eligibility Criteria

• Ages Eligible for Study: 30 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

INCLUSION CRITERIA

1. Be ≥ 30 years and ≤ 70 years.

2. Have up to 2 symptomatic femoral chondral or osteochondral defects in the index knee on the medial or lateral femoral condyles or the knee trochlea area, which are:

   1. ICRS Grade 2, 3 or Grade 4
   2. Each suitable for treatment with 1 Episealer device NOTE: Additional femoral cartilage lesions which, in the opinion of the investigator, are asymptomatic and free from underlying bone lesions (e.g., bone edema) will not be treated.

3. Have focal articular defect(s) each with a cartilage lesion area ≥ 1.5 cm2 and ≤ 7.0 cm2.

   1. Subjects with up to two defects ≥ 1.5 cm2 and ≤ 4.0 cm2, that are surrounded by adequate circumferential cartilage as determined by the investigator, will be randomized.
   2. Subjects with at least one defect > 4.0 cm2 and ≤ 7.0 cm2, with adequate bony support as determined by the investigator, will not be randomized, and will receive the Episealer device.

4. Have screening scores that meet the following criteria:

   1. Visual Analog Scale (VAS) pain score of the index knee of ≥ 40 mm
   2. KOOS Overall Score of ≤ 60
5. Have experienced knee pain symptoms and undergone prior non-surgical management (e.g., physical therapy, bracing, HA injections) for at least 4 weeks prior to being considered for the study.
6. Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study.
7. Be willing and able to comply with all study procedures including all pre-operative, post-operative, and rehabilitation requirements.

If female and of child-bearing potential, must have a negative pregnancy test prior to the surgical procedure and no intention of becoming pregnant in the next 24 months.

EXCLUSION CRITERIA

Pre-Operative Exclusion Criteria

Subjects who meet any of the following pre-operative screening criteria will be excluded from participation in this study:

1. Have a Body Mass Index (BMI) greater than 37 kg/m2.
2. Have an ICRS Grade 3 or 4 tibial lesion of any size, or an ICRS Grade 4 patella lesion/fissure ≥ 2.0 mm in width in the index knee.
3. Have malalignment of >8 degrees varus or valgus in the index knee based on standard AP x-rays.
4. Have deficits in flexion or extension of >10 degrees in the index knee as compared to the contralateral knee.
5. Have an existing prosthesis in the index knee compartment or opposing joint surface.
6. Have joint instability in the index knee due to soft tissue or muscular insufficiency.
7. Have a vascular insufficiency at the lesion site that will impair successful microfracture (e.g., avascular necrosis/osteonecrosis, osteochondritis dissecans). (NOTE: This exclusion will not apply to patients with lesions between 4.0-7.0 cm2 who will not undergo randomization and will be treated in the Episealer-only arm).
8. Have inadequate bone stock underlying the lesion site, in the opinion of the investigator.
9. Have any condition, therapy, or medication that may impair bone healing or prevent adequate implant fixation (e.g., osteoporosis).
10. Have a diagnosis of a concomitant knee injury, which in the opinion of the investigator, may confound assessment of the index knee.
11. Have any meniscus tears or defects that require resection of more than 1/3 of the meniscus in the compartment to be treated (i.e., medial meniscus when medial femoral compartment is being treated; lateral meniscus when lateral femoral compartment is being treated).
12. Have a contralateral knee with symptomatic cartilage, meniscal, or ligamentous lesions; generalized osteoarthritis, or any condition that requires surgery, which in the opinion of the investigator, may confound assessment of the index knee, or any condition that requires surgery.
13. Have any condition that is unrelated to the index knee and significantly impairs walking ability (e.g., spinal stenosis, sciatica).
14. Have undergone previous treatment with autograft or allograft transfer, synthetic plugs, or microfracture in the index knee within 6 months of screening. (NOTE: Subjects who have undergone debridement at any point in the past are not excluded).
15. Have a loss of joint space on standing radiographs (Kellgren-Lawrence Grade ≥3) in the index knee.
16. Have an active systemic infection, or an active local infection in or near the index knee, or a previous history of joint infection.
17. Have a history of rheumatoid arthritis.
18. Have known allergies to any of the materials used in the implant (i.e., Cobalt-Chrome alloy and Titanium).
19. Have a contraindication to MRI (e.g., implanted pacemaker, metallic cardiac valve(s), magnetic material such as surgical clips, stent, implanted electronic infusion pumps or any other condition that would prevent the subject from undergoing an MRI).
20. Have a known immunodeficiency including subjects who are receiving or have received corticosteroids, immunosuppressants, immunostimulating agents or radiation therapy within 6 months prior to surgery.
21. Are participating in another clinical investigation for which they received an investigational product (including, but not limited to, a drug or vaccine) within the last 60 days or report the intention to participate in another clinical investigation during the course of the study
22. Are currently abusing drugs or alcohol or have a history of the same within the last 6 months.
23. Have any mental or psychological disorder that would impair their ability to complete the study questionnaires.
24. Are currently breastfeeding or planning to breastfeed any time during the course of the study.
25. Are currently a prisoner.
26. Have significant comorbidities or conditions associated with high-risk for surgical or anesthetic survival (e.g., renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.).
27. Have any medical condition or other circumstances, in the judgment of the investigator, that might interfere with the ability to return for follow-up visits, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative rehabilitation.
28. Have any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the device's safety and performance.

Intra-operative Exclusion Criteria

Subjects who meet any of the following intra-operative screening criteria will be excluded from participation in this study:

1. Have any meniscus tears or defects that require resection of more than 1/3 of the meniscus in the compartment to be treated (i.e., medial meniscus when medial femoral compartment is being treated; lateral meniscus when lateral femoral compartment is being treated).
2. Have chondrosis of the non-operative patellofemoral compartment, contralateral compartment or medial or lateral proximal tibia greater than Outerbridge Grade 2.

3. Have an index lesion on the articular surface that lacks adequate circumferential cartilage as determined by the investigator (NOTE: This exclusion applies only to patients randomized to the microfracture arm.)

   Applicable to Investigational Group Only

4. Have a defect undergoing treatment that cannot be adequately covered by the Episealer device based on intra-operative measurements.

Have bone quality which, in the judgment of the surgeon, would prevent satisfactory fixation of the investigational device.

Contacts and Locations

Contacts

Contact: Katarina Flodström; 1 686 845 9447; Katarina.Flodstrom@episurf.com

Locations

United States, Arizona

Physicians Research Group; Recruiting

Tempe, Arizona, United States, 85284

Contact: Vianeth Santiago 480-868-7014 v.santiago@prgresearch.com

Contact: Tammy Fuentes 800-774-1534 t.fuentes@prgresearch.com

Principal Investigator: Eric Eifler, MD

United States, California

Horizon Clinical Research; Recruiting

La Mesa, California, United States, 91942

Contact: Dino Subasic, BS 619-456-6012 dino@horizontrials.com

Principal Investigator: Scott Hacker, MD

United States, Louisiana

Ochsner Sports Medicine Institute; Recruiting

New Orleans, Louisiana, United States, 70121

Contact: John Maggio 504-842-0263 jmaggio@ochsner.org

Contact: Graylin Jacobs (504) 842-0263 Graylin.jacobs@ochsner.org

Principal Investigator: Deryk Jones, MD

United States, New Jersey

Hackensack University Medical Center; Recruiting

Hackensack, New Jersey, United States, 07601

Contact: Rose Williams 551-996-4261 Rose.Williams@hackensackmeridian.org

Principal Investigator: Yair Kissin, MD

United States, New York

Plancher Orthopaedics & Sports Medicine; Recruiting

New York, New York, United States, 10128

Contact: Stephanie Petterson 203-869-2002 spetterson@ofals.org

Principal Investigator: Kevin Plancher, MD

United States, Ohio

Ohio State University; Recruiting

Columbus, Ohio, United States, 43202

Contact: Jenna DeFranco, BS 614-293-2761 Jenna.DeFranco@osumc.edu

Principal Investigator: David Flanigan, MD

United States, Tennessee

Clinical Research Solutions; Recruiting

Jackson, Tennessee, United States, 38305

Contact: Brittany Reyes, BS 731-613-8248 breyes@crssites.com

Principal Investigator: Jason Hutchison, MD

Canada, Nova Scotia

QEII Health Sciences Center; Recruiting

Halifax, Nova Scotia, Canada, B3H 2E1

Contact: Liam Rappoldt 902-473-7626 liam@drivanwong.com

Contact: Morgan King morgan@drivanwong.com

Principal Investigator: Ivan Wong, MD

Germany

Universitatsmedizin Berlin Charite; Recruiting

Berlin, Germany, 10117

Contact: Derya Belkacem 030/450 615 196 derya.belkacem@charite.de

Contact: Anne Zergiebel 030/450 515 235 anne.zergiebel@charite.de

Principal Investigator: Tobias Jung, MD

Orthocentrum Hamburg; Recruiting

Hamburg, Germany, 20149

Contact: Rene Kaiser +4940443639 kaiser@oc-h.de

Principal Investigator: Johannes Holz, MD

United Kingdom

University Hospital Coventry and Warwickshire NHS Trust; Recruiting

Coventry, England, United Kingdom, CV2 2DX

Contact: Kerri McGowan kerri.mcgowan@uhcw.nhs.uk

Principal Investigator: Feisal Shah, MD

University Hospital Southampton NHS Foundation Trust; Recruiting

Southampton, So16 6yd, United Kingdom

Contact: Michelle Beveridge +442381208141 michelle.beveridge@uhs.nhs.uk

Principal Investigator: Mark Frame, MD

Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH); Recruiting

Oswestry, United Kingdom, Shropshire SY10 7AG

Contact: Jean Denton jeandenton@nhs.net

Principal Investigator: Paul Jermin, MD

Sponsors and Collaborators

Episurf Medical Inc.

MCRA

Investigators

• Study Director: Katarina Flodström; Episurf Medical Inc.

More Information

• Responsible Party: Episurf Medical Inc.
• ClinicalTrials.gov Identifier: NCT04000659
• Other Study ID Numbers: IDE 1006
• First Posted: June 27, 2019
• Last Update Posted: December 7, 2022
• Last Verified: December 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

Keywords provided by Episurf Medical Inc.:

Knee; Cartilage